Bayer ‘deeply suspicious’ of pre-trial discovery bid in fight over Xarelto patents

Intellectual Property 2023-03-23 2:09 pm By Sam Matthews | Melbourne

German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.